Searchable abstracts of presentations at key conferences in endocrinology

ea0041s23.3 | Indications of incretin based therapies | ECE2016

The role of GLP-1 in body weight regulation: lessons from human trials

Astrup Arne

In 1996, we showed that GLP-1 is a satiety hormone in humans, and increased post-prandial GLP-1 levels following high protein meals have shown to be at least partially responsible for the high satiating effect of protein. The natural ligands to stimulate GLP-1 release seem to be peptide fragments and monoacylglycerides.The once-daily GLP-1 analogue liraglutide at doses up to 3.0 mg was compared with placebo or orlistat over 104 weeks as adjunct to diet a...

ea0022p715 | Obesity | ECE2010

Relation of weight, height and BMI of child to parental characteristics in families with obese or overweight parents before weight management: diogenes project

Kunesova Marie , Hlavaty Petr , Kalouskova Pavla , Bajzova Magda , Hlavata Karolina , Hill Martin , Saris Wim , Astrup Arne

Background: Familial resemblance was shown for body composition and risk factors in several studies. In twin studies which are powerful tool to assess genetically mediated traits significant resemblance was found in twins reared apart. In pairs of monozygotic twins was found significant resemblance in response to positive and negative energy balance. Aim of the study was to evaluate relationship of anthropometric parameters of parents and socioeconomic characteristics of famil...

ea0048p1 | Poster Presentations | SFEEU2017

Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial

McGowan Barbara , Fujioka Ken , Greenway Frank , Krempf Michel , Le Roux Carel , Vettor Roberto , Lilleore Soren , Astrup Arne

Aims/objectives: Obesity and prediabetes are risk factors for developing T2D. 5–10% weight-loss can reduce risk of developing T2D by >50%. The 3-year part of this phase 3 trial investigated effects of liraglutide 3.0 mg, as adjunct to diet+exercise, in delaying onset of T2D over 3 years, body-weight and cardiometabolic risk factors in adults with obesity or overweight with comorbidities, and diagnosed with prediabetes at screening.Methods: Indiv...

ea0081oc4.1 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Significant weight loss resulted in reduced levothyroxine requirements during a tesomet trial of hypopituitary patients with acquired hypothalamic obesity

Klose Marianne , Huynh Kim , Tfelt Jacob , Krogsgaard Kim , Drejer Jorgen , Byberg Sarah , Madsbad Sten , Magkos Faidon , Aharaz Abdellatif , Edsberg Berit , Astrup Arne , Feldt-Rasmussen Ulla

Objective: Hypothalamic obesity results in severe weight-gain and increased risk of cardiovascular and metabolic mortality. We aimed to assess the safety and efficacy of Tesomet (tesofensine plus metoprolol), and ongoing requirements in pituitary hormone replacement adjustments in adults with acquired hypothalamic obesity, a rare disease with no approved therapyResearch design, patients and methodsTwenty-one adults with hypothalami...

ea0048p11 | Poster Presentations | SFEEU2017

Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled trial

McGowan Barbara , Roux Carel Le , Astrup Arne , Fujioka Ken , Greenway Frank , Lau David , Van Gaal Luc , Ortiz Rafael Violante , Wilding John , Skjoth Trine , Pi-Sunyer Xavier

Background: The 3-year part of this trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet+exercise, in delaying onset of T2D (primary endpoint) in adults with prediabetes and obesity (BMI ≥30 kg/m2) or overweight (≥27 kg/m2) with comorbidities.Methods: Participants were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo plus 500 kcal/day deficit diet and 150...

ea0070aep1073 | Hot topics (including COVID-19) | ECE2020

A randomized-controlled trial of tesomet resulted in significant weight loss in hypopituitary patients with hypothalamic obesity

Huynh Kim , Klose Marianne , Krogsgaard Kim , Drejer Jorgen , Byberg Sarah , Madsbad Sten , Magkos Faidon , Aharaz Abdellatif , Edsberg Berit , Astrup Arne , Feldt-Rasmussen Ulla

Background and objective: Hypothalamic obesity is characterized by rapid and severe weight-gain with increased risk of cardiovascular and metabolic disorders. Currently, there are no approved or effective pharmacological treatments and conventional weight management remain largely ineffective in hypothalamic obesity. This trial investigated safety and efficacy of Tesomet (0.5 mg tesofensine and 50 mg metoprolol) in hypopituitary patients with hypothalamic obesity.<p class=...

ea0063gp139 | Obesity | ECE2019

Prediction of clinically significant weight loss with Gelesis100 in the GLOW study as early as 8 weeks post-treatment

Luzi Livio , Raben Anne , Astrup Arne , Matejkova Erika , Svacina Stepan , Gnessi Lucio , Navas-Carretero Santiago , Martinez J Alfredo , Greenway Frank , Aronne Louis , Apovian Caroline , Kaplan Lee , Hill James , Fujioka Ken , Still Christopher , Sannino Alessandro , Saponaro Cosimo , Calderon Henry , Urban Lorien , Chiquette Elaine , Leider Harry , Ron Eyal , Zohar Yishai , Heshmati Hassan

Introduction: Identification of early responders is widely used in pharmacotherapy for weight loss to minimize unnecessary exposure to risks and unnecessary expenses. Gelesis Loss Of Weight (GLOW; NCT02307279), a multicenter, double-blind, placebo-controlled pivotal study, demonstrated that Gelesis100 offers a compelling new potential approach in the management of overweight and obesity.Objective: A post-hoc area under the curve (AUC) for the receiver op...

ea0041oc12.3 | Obesity | ECE2016

Effects of weight loss and long-term weight maintenance with diets varying in protein and glycemic index on circulating pro-neurotensin in the Diet, Obesity, and Genes (DiOGenes) Study: a randomized, controlled trial

Rudovich Natalia , Bernigau Wolfgang , Pivovarova Olga , Osterhoff Martin , Sparwasser Andrea , Bergmann Andreas , Struck Joachim , van Baak Marleen A , Jebb Susan A , Papadaki Angeliki , Alfredo Martinez J , Handjieva-Darlenska Teodora , Kunesova Marie , Hager Jorg , Valsesia Armand , Viguerie Nathalie , Langin Dominique , Astrup Arne , Saris Wim H M , Pfeiffer Andreas F H

Aims: Elevated levels of neurotensin (NT), a neurotransmitter and postprandial secreted intestinal hormone, are associated with an increased risk of diabetes, cardiovascular disease and breast cancer. Here we studied the regulation of circulating pro-NT (a stable NT precursor fragment) by weight loss and dietary interventions.Methods: DiOGenes is a pan-European controlled dietary intervention study in overweight adults who first lost body weight on an 8-...